(Q43732202)

26 November 2017

title

Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions (English)

1 reference

26 November 2017

Will BP

1

1 reference

26 November 2017

Berthelot JM

2

1 reference

26 November 2017

Nobrega KM

3

1 reference

26 November 2017

Flanagan W

4

1 reference

26 November 2017

Evans WK

5

1 reference

26 November 2017

publication date

1 September 2001

1 reference

European Journal of Cancer

26 November 2017

published in

1 reference

26 November 2017

volume

37

1 reference

26 November 2017

issue

14

1 reference

26 November 2017

page(s)

1797-1804

1 reference

Cost of combined modality interventions for stage III non-small-cell lung cancer

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

Diagnostic and therapeutic approaches to lung cancer in Canada and their costs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

Management of metastatic non-small-cell lung cancer and a consideration of cost

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

Estimates of the lifetime costs of breast cancer treatment in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900204-0

7 January 2021

10.1016/S0959-8049(01)00204-0

Identifiers

DOI

1 reference

26 November 2017

1 reference